Nov 12, 2026, 5:54 PM ETMilken Institute1h 6m

Engineering the Next Era of Human Health | Future of Health Summit 2026

Conference Presentation, Panel, Fireside Chat

Event: The 2026 Future of Health Summit, themed "Better Health Within Reach," convened 200 speakers across 60+ panel sessions to address the gap between medical innovation and patient access.
Core Paradox: While screening precision, personalized cancer vaccines, and AI have moved from pilot to practice, 40 million people daily use AI chatbots for health queries, and chronic disease burdens continue to rise.
Financial Projections: Employers anticipate a median 9.2% increase in healthcare costs for 2027 alone; nearly 50% of U.S. adults report difficulty affording care.
New Initiative: The Milken Institute Women's Health Network announced the "Elevate Investment Initiative," aiming to mobilize $1 billion in net new capital for women's health, targeting the systemic underfunding of a demographic representing 50% of the global population.
Call to Action: Participants were urged to leave the summit with at least one actionable implementation plan, a new partner, and bold ideas rather than merely listening.

Nubar Fain (CEO, Flagship Pioneering): Co-founder of Moderna; focuses on inventing companies based on breakthrough innovations across 50 portfolio companies.
Chris Berner (CEO, Bristol-Myers Squibb): Represents a 170-year-old pharma giant transitioning from chemotherapy to immuno-oncology and neuroscience; emphasizes access and reimbursement challenges.
Dr. David Rue (CMO, Microsoft): Physician and technologist focusing on AI-driven outcomes, access, and shifting from reactive to proactive care models.
Robert Stone (CEO, City of Hope): Leads one of the nation's largest cancer centers, treating 200,000 patients annually across five locations; emphasizes the "Access Hope" spin-out to bring trials to community physicians.

Cell Therapy Maturation: Cell therapy is transitioning from nascent technology to standard of care for multiple myeloma and lymphoma, with potential to treat solid tumors and autoimmune diseases like lupus and MS, offering durable remissions previously deemed science fiction.
AI as "Companion Scientist": Nubar Fain projects that autonomous AI agents will accelerate the "wheel of science" (hypothesis to data interpretation), drastically shortening the timeline for understanding biology, though predicting exact cure timelines remains risky.
Moderna & Merck Data: Recent evidence from Moderna and Merck demonstrates the efficacy of tuned immune system responses in cancer, serving as a precursor to broader engineered molecular treatments.
BMS Efficiency Goals: Bristol-Myers Squibb has committed to reducing the time from Investigational New Drug (IND) to approval by 30% and improving clinical trial success prediction through AI-driven molecular tweaking.

Urban/Rural Disparity: 80% of cancer patients do not receive care at NCI-designated comprehensive centers; 50% of U.S. counties lack a practicing psychiatrist, creating "healthcare deserts."
Proactive Screening Pilot: A Microsoft pilot in East Texas utilizing 2-minute retinal scans identified that 1 in 5 patients had advanced diabetic retinopathy (average A1C of 10.5%), enabling proactive intervention for those at 100% risk of blindness.
Multi-Condition Screening: One retinal exam in the pilot was capable of screening for 7–10 conditions, finding referable cardiometabolic disease in 67% of the community population.
"Access Hope" Model: City of Hope's spin-out partnership manages 10 million patients via 800 employer clients, resulting in diagnosis or treatment plan changes in 80% of reviewed cases due to access to the newest innovations.
Systemic Bottlenecks: Current electronic health records are encounter-based, failing to capture at-risk populations who do not present for care; 50% of cancer patients currently do not receive care consistent with evidence-based guidelines.

Expectation Management: Panelists cautioned against overpromising, noting that while AI is feasible, curing complex diseases like cancer or Alzheimer's within a decade is low-probability given the system's complexity (68 trillion cells, 7 quintillion atoms).
Regulatory Parallels: Nubar Fain drew parallels between current AI anxieties and the 1975 Asilomar Conference on genetic engineering, urging the industry to proactively define responsibility and safety before accidents trigger decades of restrictive regulation (citing the Thalidomide lesson).
Liability & Oversight: Concerns were raised regarding the lack of "product liability" frameworks for AI; David Rue emphasized the need for "guardrails" and ensuring humans remain "at the center" of decision-making to prevent job displacement and ensure accountability.
False Positive Risks: Robert Stone noted that widespread screening adoption is hindered by high false-positive rates, which can overwhelm diagnostic systems and erode public trust without precise, personalized risk stratification.
Value-Based Care: The consensus is that AI must be married to value-based care models; fee-for-service structures are deemed unsustainable, and new tools allow for population-level risk monitoring essential for these models.

Medicare for All Discourse: Chris Berner argued that broad cost reduction requires structural reforms beyond political pivots, specifically citing the inability to offer equal patient support to Medicare vs. commercial patients and the need for "pay-for-performance" contracts.
Economic Impact of Screening: A 25-year study cited indicated that full adherence to colorectal, lung, breast, and cervical cancer screening saved 12 million life years and generated an estimated $6.5 trillion in economic impact.
Cost Allocation: Branded pharmaceuticals currently constitute 10–15% of total healthcare costs; panelists suggested that removing inefficiencies in the supply chain (where 50 cents of every dollar spent on branded drugs goes to non-discovery entities) is a more immediate bipartisan lever than systemic overhauls.
Data Privacy: Microsoft highlighted ongoing risks regarding sensitive patient data protection and the need for monitoring global partners to prevent nefarious actors from exploiting health data.